124 related articles for article (PubMed ID: 23074281)
1. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Fathi AT; Sadrzadeh H; Borger DR; Ballen KK; Amrein PC; Attar EC; Foster J; Burke M; Lopez HU; Matulis CR; Edmonds KM; Iafrate AJ; Straley KS; Yen KE; Agresta S; Schenkein DP; Hill C; Emadi A; Neuberg DS; Stone RM; Chen YB
Blood; 2012 Nov; 120(23):4649-52. PubMed ID: 23074281
[TBL] [Abstract][Full Text] [Related]
2. [Research Progress of Isocitrate Dehydrogenase Mutation-Positive Acute Myeloid Leukemia --Review].
Ye F; Ma J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):630-633. PubMed ID: 38660877
[TBL] [Abstract][Full Text] [Related]
3. D-2-hydroxyglutarate supports a tolerogenic phenotype with lowered major histocompatibility class II expression in non-malignant dendritic cells and acute myeloid leukemia cells.
Hammon K; Renner K; Althammer M; Voll F; Babl N; Decking SM; Siska PJ; Matos C; Conejo ZEC; Mendes K; Einwag F; Siegmund H; Iberl S; Berger RS; Dettmer K; Schoenmehl R; Brochhausen C; Herr W; Oefner PJ; Rehli M; Thomas S; Kreutz M
Haematologica; 2024 Jan; ():. PubMed ID: 38235501
[TBL] [Abstract][Full Text] [Related]
4. Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.
Emadi A; Faramand R; Carter-Cooper B; Tolu S; Ford LA; Lapidus RG; Wetzler M; Wang ES; Etemadi A; Griffiths EA
Am J Hematol; 2015 May; 90(5):E77-9. PubMed ID: 25651001
[TBL] [Abstract][Full Text] [Related]
5. Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.
Janin M; Mylonas E; Saada V; Micol JB; Renneville A; Quivoron C; Koscielny S; Scourzic L; Forget S; Pautas C; Caillot D; Preudhomme C; Dombret H; Berthon C; Barouki R; Rabier D; Auger N; Griscelli F; Chachaty E; Leclercq E; Courtier MH; Bennaceur-Griscelli A; Solary E; Bernard OA; Penard-Lacronique V; Ottolenghi C; de Botton S
J Clin Oncol; 2014 Feb; 32(4):297-305. PubMed ID: 24344214
[TBL] [Abstract][Full Text] [Related]
6. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.
Im AP; Sehgal AR; Carroll MP; Smith BD; Tefferi A; Johnson DE; Boyiadzis M
Leukemia; 2014 Sep; 28(9):1774-83. PubMed ID: 24699305
[TBL] [Abstract][Full Text] [Related]
7. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
Chaturvedi A; Araujo Cruz MM; Jyotsana N; Sharma A; Yun H; Görlich K; Wichmann M; Schwarzer A; Preller M; Thol F; Meyer J; Haemmerle R; Struys EA; Jansen EE; Modlich U; Li Z; Sly LM; Geffers R; Lindner R; Manstein DJ; Lehmann U; Krauter J; Ganser A; Heuser M
Blood; 2013 Oct; 122(16):2877-87. PubMed ID: 23954893
[TBL] [Abstract][Full Text] [Related]
8. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.
DiNardo CD; Propert KJ; Loren AW; Paietta E; Sun Z; Levine RL; Straley KS; Yen K; Patel JP; Agresta S; Abdel-Wahab O; Perl AE; Litzow MR; Rowe JM; Lazarus HM; Fernandez HF; Margolis DJ; Tallman MS; Luger SM; Carroll M
Blood; 2013 Jun; 121(24):4917-24. PubMed ID: 23641016
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.
Emadi A; Jun SA; Tsukamoto T; Fathi AT; Minden MD; Dang CV
Exp Hematol; 2014 Apr; 42(4):247-51. PubMed ID: 24333121
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.
Fathi AT; Sadrzadeh H; Comander AH; Higgins MJ; Bardia A; Perry A; Burke M; Silver R; Matulis CR; Straley KS; Yen KE; Agresta S; Kim H; Schenkein DP; Borger DR
Oncologist; 2014 Jun; 19(6):602-7. PubMed ID: 24760710
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature.
Mauceri HJ; Hanna NN; Wayne JD; Hallahan DE; Hellman S; Weichselbaum RR
Cancer Res; 1996 Oct; 56(19):4311-4. PubMed ID: 8813113
[TBL] [Abstract][Full Text] [Related]
12. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.
Chan SM; Thomas D; Corces-Zimmerman MR; Xavy S; Rastogi S; Hong WJ; Zhao F; Medeiros BC; Tyvoll DA; Majeti R
Nat Med; 2015 Feb; 21(2):178-84. PubMed ID: 25599133
[TBL] [Abstract][Full Text] [Related]
13. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
Borger DR; Goyal L; Yau T; Poon RT; Ancukiewicz M; Deshpande V; Christiani DC; Liebman HM; Yang H; Kim H; Yen K; Faris JE; Iafrate AJ; Kwak EL; Clark JW; Allen JN; Blaszkowsky LS; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Bardeesy N; Straley KS; Agresta S; Schenkein DP; Ellisen LW; Ryan DP; Zhu AX
Clin Cancer Res; 2014 Apr; 20(7):1884-90. PubMed ID: 24478380
[TBL] [Abstract][Full Text] [Related]
14. Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
Balss J; Pusch S; Beck AC; Herold-Mende C; Krämer A; Thiede C; Buckel W; Langhans CD; Okun JG; von Deimling A
Acta Neuropathol; 2012 Dec; 124(6):883-91. PubMed ID: 23117877
[TBL] [Abstract][Full Text] [Related]
15. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
[TBL] [Abstract][Full Text] [Related]
16. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.
DiNardo CD; Ravandi F; Agresta S; Konopleva M; Takahashi K; Kadia T; Routbort M; Patel KP; Mark Brandt ; Pierce S; Garcia-Manero G; Cortes J; Kantarjian H
Am J Hematol; 2015 Aug; 90(8):732-6. PubMed ID: 26016821
[TBL] [Abstract][Full Text] [Related]
17. Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia.
Fathi AT; Wander SA; Faramand R; Emadi A
Semin Hematol; 2015 Jul; 52(3):165-71. PubMed ID: 26111463
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms.
Molenaar RJ; Thota S; Nagata Y; Patel B; Clemente M; Przychodzen B; Hirsh C; Viny AD; Hosano N; Bleeker FE; Meggendorfer M; Alpermann T; Shiraishi Y; Chiba K; Tanaka H; van Noorden CJ; Radivoyevitch T; Carraway HE; Makishima H; Miyano S; Sekeres MA; Ogawa S; Haferlach T; Maciejewski JP
Leukemia; 2015 Nov; 29(11):2134-42. PubMed ID: 25836588
[TBL] [Abstract][Full Text] [Related]
19. IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia.
Ogawara Y; Katsumoto T; Aikawa Y; Shima Y; Kagiyama Y; Soga T; Matsunaga H; Seki T; Araki K; Kitabayashi I
Cancer Res; 2015 May; 75(10):2005-16. PubMed ID: 25795706
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
